Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

18F‑Florbetaben (Neuraceq®) PET/MRI Evaluation of Cardiac Amyloid

Trial Profile

18F‑Florbetaben (Neuraceq®) PET/MRI Evaluation of Cardiac Amyloid

Active, no longer recruiting
Phase of Trial: Phase 0

Latest Information Update: 01 Feb 2019

At a glance

  • Drugs Florbetaben F18 (Primary)
  • Indications Amyloidosis
  • Focus Diagnostic use
  • Most Recent Events

    • 24 Jan 2019 Status changed from recruiting to active, no longer recruiting.
    • 20 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top